Femistina versus Canephron as a prevention of urinary tract infections after midurethral sling surgery - Non-inferiority study.

Objective: Urinary tract infection (UTI) is relatively common post-operative complication following midurethral sling placement (MUS), even in cases where intraoperative antibiotic prophylaxis was given. The primary aim of this study was to investigate the non-inferiority of Femistina as compared with Canephron in reducing symptomatic UTI in first six months following surgery.
Study Design: A sample size of 144 patients per group was established, to provide at least 90% power to demonstrate the non-inferiority of phytodrug Femistina versus Canephron as a prevention of post-MUS urinary tract infection.
Results: Women suffering from stress urinary incontinence and mixed urinary incontinence (MUI) with predominant SUI symptoms as confirmed by urodymamics (n = 320) were randomized in a 1:1 ratio to Femistina (40 mg, oral, twice daily for 20 days) or Canephron (3 × 5 ml taken orally-three times daily for 4 weeks). Both groups were homogenous for age, type of operation (only TOT outside-in) and severity of illness as indicated by ICIQ-SF questionnaire. We found that symptoms of UTI were significantly lower in patients receiving Femistina. During first 6 months after surgery UTI was confirmed in only 10 patients receiving Femistina (6,25%) when compared to 25 (15,63%) subjects receiving Canephron, p < 0.007.
Conclusion: Femistina is not inferior to Canephron in preventing lower urinary tract infection after midurethral sling surgery.
Competing Interests: Declaration of Competing Interest Tomasz Rechberger – speaker for Astellas, Adamed, Bayer, Bionorica. Investigator for Bayer; Pawel Miotla – speaker for Astellas, Adamed, Bionorica, Gedeon Richter. Investigator for Bayer and Adamed; Ewa Rechberger, Andrzej Wrobel and Beata Kulik-Rechberger – no conflict of interests.
(Copyright © 2022. Published by Elsevier B.V.)